Dr. John Cush RheumNow
1 year 10 months ago
Is Pregnancy Truly the Solution for RA?
Pregnancy is perhaps the oldest treatment in rheumatoid arthritis (RA) and has been associated with a natural improvement in disease control in 50-75% of patients. Others, however, are not as successful with unchanged disease activity or… https://t.co/MesVIUl0fC https://t.co/760i5znmeu
Mrinalini Dey DrMiniDey
1 year 10 months ago
💊Dapirolizumab (DZP) is a novel CD40L inhibitor
💊Results from phase 3 trial in #SLE
💊Demonstrated improvement in disease activity & GC tapering
💊More pts on DZP achieved BICLA response vs PBO
💊DZP well tolerated
AbL16 #ACR24 @RheumNow https://t.co/dtb8QFKvlN
sheila RHEUMarampa
1 year 10 months ago
Dapirolizumab pegol (DZP) a novel drug wc inhibits CD40L signalling.
In the PHOENYCS GO trial, pts on DZP+SOC achieved BICLA response at wk 48 vs. DZP+PBO
-observed efficacy in SRI4, SLEDAI2K, LLDAS, BILAG
-reduxn in steroid dose
-well tolerated
@RheumNow #ACR24 abL16 #ACRBest https://t.co/5tj2uwqeUz
Mike Putman EBRheum
1 year 10 months ago
Allogenic CD19 CAR-NK cells in SLE, experience w/22 pts
68% LLDAS remission, no relapse
As with others, B cell reconstitution w/naive B cells & surprising safety (only 2 cases low-grade CRS)
Lots of potential; still figuring out the particulars
#ACR24 @RheumNow Abstr#L17 https://t.co/zLtMNrXIlX
sheila RHEUMarampa
1 year 10 months ago
LEVI-04 a novel neurotropin3-i showed:
-significant analgesia across all measures
-improvement in functional measures and PGA for all doses in a Ph2 RCT
- well tolerated
Hopefully will prove to be a therapeutic option for knee #osteoarthritis in future
@RheumNow #ACR24 absL15 https://t.co/kWsyyyGxyU
Antoni Chan MD (Prof) synovialjoints
1 year 10 months ago
Late breaking abstract L19
Study on the efficacy & safety of Emapalumab in treating Macrophage Activation Syndrome (MAS) in Still's Disease.
Key findings:
- 53.8% achieved complete response (CR) at Week 8; 85% at any time.
- Rapid reduction in hyperinflammation biomarkers… https://t.co/VcmUdRP6PV https://t.co/r7AMt0IjYk
Richard Conway RichardPAConway
1 year 10 months ago
Grom et al. Emapalumab (anti-IFNg) in MAS in Stills. 39 patient pooled analysis. 54% complete response at week 8, 85% at any time. Clinically meaningful glucocorticoid reduction in 72%. @RheumNow #ACR24 Abstr#L19 https://t.co/U72KCfsUh7 https://t.co/jNxsvhseVf
One of the hot topics during the meeting was gender differences in SpA. Three abstracts presented addressed issues related to these differences particularly in the aspects of treatment response and disease activity.
Janet Pope Janetbirdope
1 year 10 months ago
Sustained Complete Renal Remission
➡️v strict endpoint in #lupus #nephritis trial from 1 yr to 3yr f/u
▶️all added to #LN SoC
#Voclosporin 20.1% vs #placebo 11.8%
Better if 1 visit only didn’t meet endpoint
➡️ then 10% more per group
ACRBest ACR24 @ACRheum @RheumNow abst1545
Richard Conway RichardPAConway
1 year 10 months ago
Conaghan et al. LEVI-04, neurotrophin-3 inhibitor in knee OA. 518 patients. Significant improvements in WOMAC pain and function, and PGA. So sign of any increase in rapidly progressive OA (as with NGF inhibitors) @RheumNow #ACR24 Abstr#L15 https://t.co/qud4wTAikY https://t.co/0wjjG4U4bf
Antoni Chan MD (Prof) synovialjoints
1 year 10 months ago
Late breaking abstract L16
Dapirolizumab Pegol showed significant improvement in SLE disease activity in our Phase 3 trial.
Key findings:
- 49.5% of patients achieved BICLA response at Week 48 vs 34.6% on placebo (p=0.0110).
- 60.1% achieved SRI-4 response vs 41.1% on placebo… https://t.co/ZawdsLOxmK https://t.co/gpV3KayIW1
Mike Putman EBRheum
1 year 10 months ago
PHOENYCS GO, RCT of dapirplizumab, novel CD40Li in SLE
Met primary endpoint (NNT~6 for BICLA) & numerical improvements in many other endpts
1 MI & 1 death from infection over 213 pts
Encouraging for sure! Second phase 3 being launched
#ACR24 @RheumNow Abstr#L16 #ACRbest https://t.co/QwDMKjhFvb
